Triple-positive profile may flag adverse prostate cancer pathology

• by Andrea Surnit

• September 8, 2026

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.

• by Kerri Miller

• April 22, 2026

• 7 min

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

• by Kathryn Wighton

• June 26, 2026

• 3 min

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

• by Arthur Allen

• May 15, 2026

• 9 min